The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
The company will try to get the Komzifti QTc prolongation warning removed.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
It’s less about being fast, more about producing a better product.
Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
